Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
TPG Capital $1.1 billion take-private acquisition of Convey Health Solutions
We are advising TPG Capital on the transaction
Dynamics Special Purpose Corp. completed combination with Senti Biosciences
We advised Dynamics Special Purpose Corp. on this transaction
InSilico Medicine $60 million Series D financing
We are advising InSilico Medicine in connection with its $60 million Series D financing
Astorg acquisition of OPEN Health
We are advising Astorg on the transaction
GSK $3.3 billion acquisition of Affinivax
We are advising GSK on the acquisition
Laekna Therapeutics $61 million Series D financing
We are advising Laekna Therapeutics in connection with its Series D financing
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
Anthem $1.3 billion senior notes offering
The investment-grade notes are due 2032 and 2052
Deciphera Pharmaceuticals $172.5 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
HilleVax $200 million IPO
The shares are listed on the Nasdaq Global Select Market